Zydus Lifesciences Limited has informed the Exchange regarding a press release dated May 08, 2025, titled "Zydus receives final approval from USFDA for Glatiramer Acetate Injection, the generic version of Copaxone? 20 mg/ml, 40 mg/ml, Single-Dose Prefilled Syringes".
Press Release May 08 2025
Filed with NSE · · 3 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has announced that it received final approval from the USFDA for Glatiramer Acetate Injection, a generic version of Copaxone, in single-dose prefilled syringes. This approval allows Zydus to provide a cost-effective treatment option for patients with relapsing forms of Multiple Sclerosis. The press release emphasizes Zydus' commitment to developing complex generics and expanding therapeutic choices for patients.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Zydus Receives Final Approval From USFDA for Glatiramer Acetate Injection, the Generic Version of Copaxone® 20 mg/ml, 40 mg/ml, Single-Dose Prefilled Syringes
- Press Release Apr 30 2025
- Press Release Apr 26 2025
- Press Release Apr 25 2025
- ITC Reversal Of Common ITC U/s17(2) Required In Relation To Activity Of Subscription And Redemption Of Mutual Funds
Later from Zydus Lifesciences
- Press Release May 14 2025
- Press Release May 20 2025
- Press Release May 23 2025
- Press Release May 28 2025
- Zydus Lifesciences Limited Press Release Jun 02 2025
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences